Neoplasms of terminally differentiated B lymphocytes.
The pathophysiology of, and diagnostic criteria for, multiple myeloma are discussed. There is evidence that the malignant cell population in multiple myeloma may retain at least some capacity for immune modulation/inhibition. As the molecular biology of this disease progresses, clinical access to proliferation manipulation may become possible.
Holbert
J M
JM
Department of Pathology, Baptist Memorial Hospital, Memphis, Tennessee.
D001402:B-Lymphocytes; D001853:Bone Marrow / Q000473:pathology; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000175:diagnosis / Q000276:immunology / Q000473:pathology; D010266:Paraproteins / Q000032:analysis*; D010950:Plasma Cells / Q000276:immunology / Q000473:pathology*
D010266:Paraproteins